SMC Advice - Formulary Decisions September - October 2016

Scottish Medicines Consortium Recommendations

Medicine / Condition being treated / NHS Board decision / Date of NHS Board decision
rilpivirine/emtricitabine/tenofovir alafenamide 200mg/25mg/25mg film-coated tablets (Odefsey®)
1189/16 SMC Advice / Indication under review: treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV1 RNA ≤100,000 copies/mL. / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Decision expected by December 2016.
Updated January 2017 - not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.
FF Chapter 5 / 23 November 2016
25 January 2017
aflibercept 40mg/mL solution for injection (Eylea®)
1186/16 SMC Advice / Indication under review: for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV). / Routinely available in line with national guidance.
FF Chapter 11 / 23 November 2016
progesterone 100mg vaginal tablets (Lutigest®)
1185/16 SMC Advice / Indication under review: Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women. / Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicines.
Chapter 7 / 23 November 2016
budesonide 9mg prolonged release tablet (Cortiment®)
1093/15 SMC Advice / Indication under review: in adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient.
SMC restriction: for use in patients with UC who present with active left-sided disease and/or proctosigmoiditis who are not suitable for oral prednisolone, as an alternative to budesonide rectal formulations or off-label oral budesonide. / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Decision expected by December 2016.
Updated January 2017 - not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.
FF Chapter 1 / 23 November 2016
25 January 2017
golimumab (Simponi®) 50 mg solution for injection
1199/16 SMC Advice / In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate. / Not available as not recommended for use in NHSScotland
1199/16 SMC Advice / 23 November 2016
perampanel (Fycompa®) 2mg, 4mg, 6mg, 8mg, 10mg and 12mg film-coated tablets
1200/16 SMC Advice / Indication under review: Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. / Not available as not recommended for use in NHSScotland
1200/16 SMC Advice / 23 November 2016
budesonide/formoterol 200 micrograms/6 Inhalation powder and 400 micrograms/12 Inhalation powder (Symbicort Turbohaler®)
budesonide/formoterol 200 micrograms/6 micrograms per actuation, pressurised inhalation, suspension (Symbicort®)
1198/16 SMC Advice / Indication under review: Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy / Not available as not recommended for use in NHS Scotland.
1198/16 SMC Advice / 23 November 2016
tocilizumab (RoActemra®) 162mg Solution for Injection in Pre-Filled Syringe
1201/16 SMC Advice / Indication under review: Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. / Not available as not recommended for use in NHSScotland
1201/16 SMC Advice / 23 November 2016
lenvatinib 4mg and 10mg hard capsules (Lenvima®)
1179/16 SMC Advice / Indication under review: treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Updated November 2016 – routinely available in line with regional guidance. / 23 November 2016
November 2016
nivolumab, 10mg/mL, concentrate for solution for infusion (Opdivo®)
1180/16 SMC Advice / Indication under review: treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
SMC restriction: treatment with nivolumab is subject to a two-year clinical stopping rule. / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Updated January 2017 – routinely available in line with national guidance. / 23 November 2016
January 2017
sofosbuvir 400mg, velpatasvir 100mg film-coated tablets (Epclusa®)
1195/16 SMC Advice / Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.
SMC restriction: in patients with genotype 3 (GT3) chronic HCV infection / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Decision expected by December 2016.
Updated January 2017 – routinely available in line with national guidance.
1195/16 SMC Advice / 23 November 2016
25 January 2017
pegaspargase (Oncaspar®) 750U/mL solution for injection/infusion
1197/16 SMC Advice / Indication under review: as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. / Available in line with national guidance.
1197/16 SMC Advice / 23 November 2016
dequalinium chloride 10mg vaginal tablets (Fluomizin®)
1194/16 SMC Advice / Indication under review: Treatment of bacterial vaginosis.
SMC restriction: In patients for whom the initial treatment is not effective or well tolerated. / Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicines. / 23 November 2016
migalastat, 123mg hard capsules (Galafold®)
1196/16 SMC Advice / Indication under review: long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.
SMC restriction: in males with classic mutations (leucocyte enzyme activity <1%) treatment should commence at diagnosis; in females and those males with later onset mutations with higher levels of leucocyte enzyme activity, treatment should commence when patients experience uncontrolled pain, evidence of renal, cardiac or neurovascular disease, or gastrointestinal symptoms that significantly reduce quality of life. / Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicines. / 23 November 2016
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)
1187/16 SMC Advice / Indication under review: in combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.
SMC restriction: for the first-line treatment of advanced melanoma / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Updated January 2017 – routinely available in line with national guidance. / 23 November 2016
January 2017
olaparib, 50mg, hard capsules (Lynparza®)
1047/15 SMC Advice / Indication under review: monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. / Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts.
Await SCAN submission and decision by Lothian formulary committee / 23 November 2016
adalimumab (Humira®) 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen
adalimumab (Humira®) 40mg/0.8ml Pre-filled Syringe and Pre-filled Pen
adalimumab (Humira®) 40mg/0.8ml vial for paediatric us
1208/16 SMC Advice / Indication under review: Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies / Not available as not recommended for use in NHSScotland
1208/16 SMC Advice / 23 November 2016
adalimumab (Humira®) 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen
adalimumab (Humira®) 40mg/0.8ml Pre-filled Syringe and Pre-filled Pen
1209/16 SMC Advice / Indication under review: Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. / Not available as not recommended for use in NHSScotland
1209/16 SMC Advice / 23 November 2016
canakinumab (Ilaris®) 150mg powder for solution for injection
1210/16 SMC Advice / Indication under review: Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate. / Not available as not recommended for use in NHSScotland
1210/16 SMC Advice / 23 November 2016
lenalidomide (Revlimid®) 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules
1211/16 SMC Advice / Indication under review: Treatment of adult patients with relapsed or refractory mantle cell lymphoma. / Not available as not recommended for use in NHS Scotland.
1211/16 SMC Advice / 23 November 2016
fampridine 10mg prolonged-release tablets (Fampyra®)
789/12 SMC Advice / Indication under review: For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7). / Not available as not recommended for use in NHSScotland
789/12 SMC Advice / 23 November 2016
nivolumab, 10mg/mL, concentrate for solution for infusion (Opdivo®)
1188/16 SMC Advice / Indication under review: as monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults. / Not available as not recommended for use in NHSScotland
1188/16 SMC Advice / 23 November 2016

1 of 3